SpliceBio: Valuation, Funding & Investors
Baldiri Reixac 10-12 Parc Cientific de Barcelona Barcelona, Barcelona 08028, EShttps://www.splice.bio/Precision Medicine
SpliceBio is a clinical-stage genetic medicines company specializing in Protein Splicing technology to treat diseases caused by mutations in large genes. The company is advancing its lead program, SB-007, for Stargardt disease and is developing a broader pipeline targeting indications in ophthalmology, neurology, and other therapeutic areas.
Leadership & Board
- Current Number of Employees
- 57
- Current LinkedIn Followers
- 12,013
Latest Estimated Valuation
- Total Amount Raised
- $135M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $135M
- Latest Funding Round
- Series B
Employee Trend
SpliceBio had 57 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
57Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
SpliceBio had 12,013 followers as of October 26, 2026. The number of followers increased by 38 (0.32%) week-over-week.
12,013Latest Followers Count
38(0.32%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jun 11, 2025 | Series B | $135.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| EQT Life Sciences | Series B |
| New Enterprise Associates | Series B |
| Gilde Healthcare | Series B |
| Sanofi Ventures | Series B |
| Roche Venture Fund | Series B |
| UCB Ventures | Series B |
| Ysios Capital | Series B |
| Novartis Venture Fund | Series B |
Similar Companies
A snapshot of private companies similar to SpliceBio, helping you discover and navigate related company profiles.
Related News and Analysis
